Description of HL and its treatment
| Characteristics . | Patients, n = 67 . |
|---|---|
| Localized HL, n (%) | 46 (68.7) |
| Disseminated HL, n (%) | 21 (31.3) |
| Standard treatment | |
| ABVD, n (%) | 37 (55.3) |
| EBVM, n (%) | 9 (13.4) |
| Reinforced treatment without ASCT, n (%) | 13 (19.4) |
| «BEACOPP-like» | 5 |
| VABEM | 8 |
| Reinforced treatment with ASCT, n (%) | 8 (11.9) |
| ABVD + ASCT | 5 |
| Second line + ASCT | 3 |
| Radiotherapy, n (%) | 66 (98.5) |
| Number of cycles, median [min-max] | 3 [1-5] |
| Characteristics . | Patients, n = 67 . |
|---|---|
| Localized HL, n (%) | 46 (68.7) |
| Disseminated HL, n (%) | 21 (31.3) |
| Standard treatment | |
| ABVD, n (%) | 37 (55.3) |
| EBVM, n (%) | 9 (13.4) |
| Reinforced treatment without ASCT, n (%) | 13 (19.4) |
| «BEACOPP-like» | 5 |
| VABEM | 8 |
| Reinforced treatment with ASCT, n (%) | 8 (11.9) |
| ABVD + ASCT | 5 |
| Second line + ASCT | 3 |
| Radiotherapy, n (%) | 66 (98.5) |
| Number of cycles, median [min-max] | 3 [1-5] |
EBVM, epirubicin, bleomycin, vinblastine, methotrexate.